CervoMed is trading 14.1% higher at $1.78 in pre-market, amid broader healthcare strength; no company-specific catalyst has been confirmed.
- No clear company-specific announcement dated November 5 explaining the move surfaced in the search.
- The latest company news found was published October 29 and covered previously reported clinical-trial results and research publications, not a new catalyst.